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Abstract
Trial design
The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients
receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral
triple treatment with a boosted protease inhibitor (TT).
Methods
This was a 24-week, open-label, multicentre study in virologically-suppressed HIV-infected
participants (N = 225) with a 2:1 randomization: 146 patients who switched to MT were com-
pared with 79 patients who remained on a TT regimen. The primary endpoint was change in
patient-reported outcomes in quality of life as measured by the MOS-HIV and EQ-5D ques-
tionnaires. Secondary endpoints included treatment adherence, patient satisfaction, inci-
dence of adverse events and differences in plasma HIV-1 RNA viral load (VL) and CD4 cell
counts.
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Results
Baseline quality of life, measured with the MOS-HIV score, was very good (overall score of
83 ± 10.5 in the MT arm and 82.3 ± 11.3 in the TT arm) and suffered no change during the
study in any of the arms (at week 24, 83.5 ± 12.2 in MT arm and 81.9 ± 12.7 in TT arm), with-
out statistically significant differences when compared. In regards to adherence to therapy
and patient satisfaction, some aspects (number of doses forgotten in the last week and sat-
isfaction of treatment measured with the CESTA score, dimension 1) improved significantly
with MT. There were also no differences in the incidence and severity of adverse events,
even though 22.8% of those in the MT arm switched their treatment when they were
included in the study. Moreover, there was also no significant difference between the immu-
nological and virological evolution of MT and TT. In the MT arm, the VL was always unde-
tectable in 83% of patients (vs 90.7% in the TT arm) and there were only 6.7% of virological
failures with VL > 50 copies/mL (vs 2.3% in the TT arm), without resistance mutations and
with resuppression of VL after switching back to TT.
Conclusions
In a new clinical trial, monotherapy as a treatment simplification strategy in HIV-1 infected
patients with sustained viral suppression has demonstrated quality of life, safety and effi-
cacy profiles comparable to those of conventional triple therapy regimens.
Introduction
With the introduction of highly active antiretroviral therapy (HAART), HIV-1 infection has
evolved from a fatal disease to a manageable chronic condition. Central goals of current HIV
research are to avoid side effects associated with long-term therapy, promote patient comfort
and compliance, and reduce economic costs. The standard treatment with three antiretroviral
agents, usually two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus either
a boosted protease inhibitor (PI), an integrase inhibitor (II), or a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) [1] is not exempt from risks, including the emergence of drug
resistance and, principally, long-term toxicity. Some NRTIs can cause mitochondrial damage,
which in turn, results in NRTI-related adverse events such as peripheral neuropathy, pancrea-
titis, liver disturbances, renal disease, lactic acidosis, bone mineral density loss or lipoatrophy
[2, 3]. Furthermore, triple therapy (TT) regimens entail high economic costs and when co-for-
mulation is unavailable or restricted, a less convenient regimen is necessary which may lead to
low treatment adherence or dissatisfaction, which may potentially jeopardize treatment
efficacy.
During the last decade, the use of simplification regimens [4], initiated once the patient has
become stable and virologically suppressed, has become more attractive. Putative advantages
of monotherapy (MT) strategies include decreases in toxicity, antiretroviral interactions, treat-
ment complexity and cost, as well as preserving future treatment options, as the PIVOT study
has recently shown [5]. Lopinavir/ritonavir (LPV/r) is a suitable candidate for single drug
maintenance therapy due to its efficacy and high genetic barrier to resistance, which requires
the accumulation of multiple mutations [6–9]. The emergence of resistance mutations in the
protease gene are rare and have shown limited clinical significance [10–13]. Several clinical
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trials have addressed the efficacy of an LPV/r simplification strategy versus maintenance triple
therapy [11, 14–19]. After 2 to 4 years of follow-up, different studies have shown that MT can
maintain HIV viral suppression in a large proportion of patients [11, 19, 20]. MT is also the
preferred salvage therapy for first line failures in developing countries as per WHO HIV treat-
ment guidelines [21]. This has recently been challenged by the EARNEST study [22]. Further-
more, patients who experience viral load blips and emergence from suppression during MT
can be safely reinduced with prior nucleosides without any apparent loss of therapeutic
options, sparing other treatment classes for later use [11, 14–17, 20]. In Spain, as in the Euro-
pean EACS Guidelines, simplification to MT has been included since January 2008 in treat-
ment guidelines as a therapeutic option for patients with no history of prior PI failure,
undetectable viral load (VL) (<50 copies/mL) for at least six months, and signs and/or symp-
toms of toxicity from NRTIs [21]. In addition, pharmacoeconomic analysis of MT within the
Spanish public health system was demonstrated to be a more affordable strategy than triple
therapy [23–25].
However, poor treatment satisfaction is a significant risk factor for loss of viral control in
patients undergoing antiretroviral therapy, including MT [11, 26]. To investigate the degree of
patient compliance with this simplification treatment, we undertook a clinical trial that sought
to measure the impact of two alternative regimens containing boosted PIs (MT vs TT) on
patients’ quality of life, treatment satisfaction, compliance and tolerance, as well as virological
efficacy.
The primary objective was to compare quality of life in patients who started MT with LPV/r
versus patients continuing on TT containing a PI.
Secondary objectives were to compare MT vs TT with regard to treatment satisfaction,
adherence, tolerability, regimen safety and virological and immunologic efficacy.
Methods
Study design
This was a phase IV national, open-label, multicentre, controlled, randomized (2:1), 24-week
follow-up trial in HIV infected patients. The study was conducted at 31 different Spanish hos-
pitals and was sponsored by the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). The
trial protocol was approved in advance by Ethics Committees from each participating hospital,
and by a Reference Ethics Committee, representing all of them, the CCEIBA (Comite´ Coordi-
nador de E´tica de la Investigacio´n Biome´dica de Andalucı´a [Andalusian Biomedical Research
Ethics Coordinating Committee]) in November 2009. It met the ethical principles specified in
the Declaration of Helsinki and international good clinical practice guidelines, and was regis-
tered in December 2009 under EudraCT number 2009-014430-25. The authors confirm that
all ongoing and related trials for this drug/intervention are registered. Written informed con-
sent was obtained from each patient prior to any study procedures being performed. A pseu-
dorandom number generator algorithm [27, 28] was used to prepare a randomisation list,
which was held by a qualified contract research organization (CRO), not accessible to
researchers, who were informed of the assigned treatment by telephone. Randomization was
centralized and stratified by study centre, and each centre was regarded as a stratum. The size
of the block was 4 to balance treatment arms of the global sample and within each centre.
There was no further planned stratification by any other factor. The randomization list was
centralized and hidden from researchers. Clinicians were informed of the treatment assigned
to each patient by telephone consultation after they had confirmed, by fax, that the patient
met all the inclusion and none of the exclusion criteria. The QoLKAMON trial is registered in
ClinicalTrials.gov (number NCT01166477).
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Eligibility criteria
Patients over 18 years of age, with a positive HIV-1 antibody and/or PCR test, receiving any
TT containing a boosted PI, and with undetectable VL (<50 viral RNA copies/mL) during the
six months prior to enrolment were eligible for this study. For women with childbearing
potential, a negative urine pregnancy test in the initial screening was mandatory. Patients were
ineligible if any of the following conditions were present: pregnancy or nursing, acute hepati-
tis, documented resistance to LPV/r or failure on a PI therapy, concomitant therapy with
drugs contraindicated for use with LPV/r, known history of drug addiction or chronic alcohol
consumption, current active opportunistic infection or documented infection within 4 weeks
of screening, renal disease with creatinine clearance<60 mL/min, concomitant use of nephro-
toxic or immunosupressor drugs including corticosteroids, interleukin-2 or chemotherapy,
prior medical history of psychiatric disorders such as depressive syndrome, schizophrenia or
psychotic disease. Patients took Kaletra (lopinavir 200mg/ritonavir 50mg), 2 tablets bid. A pro-
tocol amendment modified the initial exclusion criterion (CD4 cell count nadir < 100 cells/
μL) to allow any CD4 cell nadir, provided that the current CD4 count was > 250 cells/μL. In
total, 46 patients had a nadir< 100 cells/μL.
Outcome measurements
Patients’ overall quality of life was assessed using the Medical Outcomes Study HIV Health
Survey (MOS-HIV) and EQ-5D questionnaires [29]. The MOS-HIV is a 35-item questionnaire
that evaluates the following 10 dimensions of quality of life: general health perceptions, pain,
physical functioning, role functioning, social functioning, mental health, energy/fatigue, health
distress, cognitive functioning, and overall quality of life. Physical health summary (PHS) and
mental health summary (MHS) scores are generated from some of the MOS-HIV dimensions,
on a scale of 0–100, with higher scores indicating better health status. The EQ-5D is a 5-item
instrument that measures mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. Index scores range from 0 to 100 where higher scores indicate better health. To
measure adherence, a validated adherence questionnaire (from the GEEMA study) was
employed [30], which includes 6 items recording multidimensional adherence measurements
versus missed-dose measurements, the classification of adherence as a dichotomous (adher-
ent/non-adherent) variable, and the time interval evaluated (weeks versus days). The visual
analogue scale (VAS) is a subjective evaluation of the patient’s own level of compliance with
the treatment and classifies adherence as a continuum variable, being 0 and 100 the worst and
best health perceptions, respectively [31]. Patient satisfaction was evaluated using the CESTA
questionnaire (Spanish Questionnaire of Satisfaction with Antiretroviral Treatment), which is
an ad-hoc questionnaire developed to assess satisfaction in patients switching to a simplified
regimen, addressing general health status, treatment, illness control, side effects, number of
pills and doses, and dietary differences. This questionnaire has two dimensions, the first one
related to the degree of treatment satisfaction and the second one to the assessment of factors
determining patient satisfaction [32].
Safety was determined by the incidence of treatment adverse events, differences between
arms in vital signs and clinical laboratory data, especially regarding HIV-1 RNA levels and
CD4 cell counts. Adverse events were graded according to Common Toxicity Criteria [33].
Serious events were adverse events grade IV. Grade I events were classified as mild, grade II as
moderate and grade III as severe. The relationship of adverse effects to treatment was based on
the judgment of the physician.
The virological efficacy was assessed in different ways. Strict virological failure was defined
by two consecutive measurements of plasma HIV-1 RNA > 500 copies/mL separated by at
Quality of life and efficacy in HIV patients on lopinavir/ritonavir monotherapy
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least two weeks. During virological failure, HIV genotyping was performed to determine resis-
tance mutations. In the MT arm, virological rebounds were not considered as therapeutic fail-
ure if there was no evidence of LPV/r genotypic resistance and viral suppression could be
reinduced with the addition of two NRTIs, leading to a subsequent decrease in VL of at least
tenfold in four weeks and to < 50 copies/mL of HIV-1 RNA after 16 weeks. However, an ITT
analysis in which analogous reintroduction meant a failure was also performed. The ability of
the two strategies to maintain VL lower than 50 and 200 copies/mL was also assessed, and
major virological efficacy was defined as undetectable VL during the whole follow-up period
and at week 24.
Study evaluations
Patients were assessed at baseline, week 12, and week 24. At each time point, the following
were obtained: a clinical assessment, list of concomitant medications, adverse events, GEEMA,
VAS and CESTA questionnaires, VL, CD4 cell count, liver enzymes, biochemistry and hema-
tologic values. MOS-HIV and EQ-5D questionnaires were completed at the first and last
assessments. An extra set of data was collected on week 4 for the experimental arm, that
included VL and CD4 cell count, GEEMA, VAS, and CESTA questionnaires, and information
on concomitant medications and adverse events.
Statistical analysis
Sample size calculations for the current study were based on the expected difference between
the two treatment arms. It was estimated, according to the literature [34], that in order to
detect as statistically significant a relative improvement in quality of life of 10% in the experi-
mental arm, with 80% power and a two-tailed significance level of 5%, a total of 390 fully evalu-
able patients (248 and 130 in each group) would be required. The study was discontinued by
the sponsor after enrolment of 228 patients, due to a lower than estimated enrolment rate, and
the final statistical power achieved was 59%. Treatment arms were compared using the Fisher’s
exact test for categorical variables and the Student’s t-test and the non-parametric Wilcoxon or
Mann-Whitney tests for continuous variables. The significance threshold was set at P = 0.05.
Baseline characteristics of study groups were also compared using an analysis of variance
(ANOVA). The main endpoint was ascertained from all the MOS-HIV scores and EQ-5D
questionnaire outcomes. The odds ratio of virological rebound was calculated.
For all analyses, the primary population included all patients from the control arm and
those from the experimental arm who received at least one dose of LPV/r (ITT: intention-to-
treat population; n = 225). In some particular cases, such as MOS-HIV evaluation, an analysis
of covariance (ANCOVA) was used for comparisons between both treatment arms, including
baseline values, sex, and age as covariates.
Results
Between February 2010 and June 2011, 225 patients were identified as eligible for the study
and were randomized: 146 patients switched to MT and 79 patients remained on TT. At the
beginning of the study, 77.2% of patients in the TT arm were taking lopinavir/ritonavir, while
the remaining patients were taking fosamprenavir, saquinavir, atazanavir, darunavir, and nelfi-
navir. Furthermore, 90% of them were using two NRTIs, the most common being TDF/FTC
(53%), followed by ABC/3TC (19%). Overall, 129 patients in the MT arm and 68 patients in
the TT arm were still in the study at week 24 (Fig 1). Of the 79 randomized patients in the con-
trol arm, 5 withdrew consent to the study, 2 were lost to follow-up, 2 were non-adherent, 1
experienced toxicity and 1 had a drug abuse relapse. Of the 146 patients from the experimental
Quality of life and efficacy in HIV patients on lopinavir/ritonavir monotherapy
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arm, 6 were lost to follow-up, 3 withdrew consent, 2 had adverse events, 4 had virological fail-
ure, 1 suffered toxicity and 1 had a drug abuse relapse.
Baseline characteristics
Baseline characteristics of the patients included in the study were not significantly different
between the two groups, TT and MT, in the majority of measured parameters (Table 1). Mean
age at screening was 45 years. Patients were predominantly male (71.4% and 71.8% respec-
tively) with a mean time since HIV diagnosis of 12.8 ± 7 and 13.5 ± 7 years. At baseline, the
mean CD4 cell count in both groups was > 600 cells/μL (720 ± 318 for the experimental arm
and 611 ± 267 for the control arm, P< 0.01). As required per protocol, all patients had unde-
tectable plasma HIV-1 RNA (< 50 copies/mL). A total of 73 patients in the MT arm and 39 in
the TT arm were included with a CD4 nadir < 200 cells/μl; 28 patients in the MT arm and 18
in the TT arm had a nadir < 100 cells/μl.
Fig 1. CONSORT flow diagram showing disposition of patients throughout the study from baseline to week 24.
https://doi.org/10.1371/journal.pone.0195068.g001
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Quality of life evaluation
At baseline, the mean MOS-HIV overall scores were 83.0 ± 10.5 in the MT arm and
82.3 ± 11.3 in the TT arm (Table 1). An analysis of covariance (ANCOVA) was performed for
comparisons between both treatment arms, including baseline values, sex, and age as covari-
ates. There were no significant differences between treatment arms in mean MOS-HIV overall
scores at week 24 (83.5 ± 12.2 vs 81.9 ± 12.7 for the experimental and control arms, respec-
tively; mean difference: 1.6; CI 95%: -1.8–5.0; P = 0.366) (Fig 2). Moreover, regarding the phys-
ical and mental components of MOS-HIV, no significant differences were observed on the
PHS (56.9 ± 6.5 and 56.3 ± 6.9; mean difference: 0.6; CI 95% -1.2–2.4; P = 0.356) and MHS
(56.4 ± 7.2 and 56.4 ± 6.9; mean difference: 0.0; CI 95%: -2.0–2.0; P = 0.762) final scores
between the experimental and control arms.
Concerning the EQ-5D questionnaire, the baseline scores were 81.8 ± 18.2 in the MT arm
and 82.6 ± 15.7 in the TT arm (Table 1). The ANCOVA analysis showed that the EQ-5D final
scores at week 24 were also similar (81.3 ± 21.9 and 83.5 ± 20.1; mean difference: -2.2 CI 95%
-8.1–3.7; P = 0.704) betwee the control and experimental arms (Fig 2).
Treatment adherence
Adherence rates (as GEEMA overall) were similar in both boosted PI-based regimens with no
significant change over time (Fisher exact test at last visit, P = 1). At the beginning and end of
the study, 74.1% and 70.1% of patients in the MT arm and 70% and 69.4% of patients in the
TT arm were fully adherent to treatment, respectively. When all the items included in the
GEEMA questionnaire were analysed separately, there were statistical differences only in the
Table 1. Patient demographics and baseline characteristics for the ITT population.
MT TT P value
Age (years)
Mean ± SD 44.5 ± 8 45.2 ± 9 0.745
Gender
Male; N (%) 102 (71.8) 55 (71.4) 1
Time from HIV diagnosis (years) 13.5 ± 7 12.8 ± 7 0.587
HIV treatment (years) 8.83 ± 5.45 9.06 ± 5.32 0.637
Risk factor for acquiring HIV N (%)
Homosexual 37 (25.3) 23 (29.1) 0.636
Heterosexual 39 (26.7) 27 (34.2) 0.283
Blood transfusion 1 (0.7) 1 (1.3) 1
IV drug user 66 (45.2) 28 (35.4) 0.202
Others 5 (3.4) 3 (3.8)
Absolute CD4+ count (cell/mm3)
Mean (SD) 719.99 ± 317.77 610.93 ± 266.88 0.01
CD4 (%) 30.87 ± 9.19 27.92 ± 9.14 0.027
Viral load (RNA copies/mL)
Mean (SD) 26.85 ± 17.31 25.45 ± 11.99 0.306
MOS-HIV overall score
Mean (SD) 83.0 ± 10.5 82.3 ± 11.3
EQ-5D overall score
Mean (SD) 81.8 ± 18.2 82.6 ± 15.7
ITT, intent-to-treat; HIV, human immunodeficiency virus; MT, monotherapy; SD, standard deviation; TT, triple therapy.
https://doi.org/10.1371/journal.pone.0195068.t001
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number of doses missed within the last week, which were more numerous in the TT arm
(85.4% of the experimental arm did not miss any dose, versus 77.3% of the control arm,
P = 0.05) (S1 Table). In the MT arm, the reason for not taking the pills was “forgetfulness” in
12.3% of the cases, and a similar figure was obtained for the TT arm (12.0%, P = 1.0; at last
visit). There was no significant difference between the mean values of the VAS scale over time
for subjects in the MT (92.8 ± 14.6 at last visit) and TT (92.9 ± 12.8 at last visit) arms nor
between them (P = 0.197) (Fig 2).
Patient satisfaction
Comparing both treatment arms, there was a significant difference in the mean score measur-
ing the change in dimension 1 (3.9 ± 11.6 of MT vs 1.2 ± 8.8 of TT, P = 0.043), and specifically,
a significantly greater satisfaction with the number of pills taken daily (P<0.001) among the
patients in the monotherapy arm versus the TT arm (S2 Table).
Safety and tolerability
There was no significant difference in the incidence of adverse events between treatment arms.
Total and serious adverse events were reported in 17.8% and 4.1% of patients from MT versus
14.3% and 1.3% from TT (P = 0.573 and P = 0.426). The non-serious adverse events were mild
in 81.1% and 58.8% in MT and TT arms respectively and considered unrelated to treatment in
83.8% and 82.4% of cases (Table 2).
There were no significant differences for haematological parameters, vital signs and anthro-
pometric measures over time either in each arm or between arms.
Virological and immunologic responses
As to maintaining virological suppression, there were no significant differences between MT
and TT arms. In the ITT analysis (where analogue introduction = failure), the percentages of
patients with undetected VL (< 50 copies/mL) at any time during the study period were
Fig 2. Final scores (mean values at week 24 with error bars showing 95% confidence intervals) of the 5
questionnaires evaluating the quality of life of both groups.
https://doi.org/10.1371/journal.pone.0195068.g002
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similar in both treatment arms (78.6% for MT vs 87% for TT; P = 0.148). Likewise, there was a
similar percentage of subjects who, at the end of the study, had VL< 50 copies/mL (84.1% for
MT vs 89.6% for TT, P = 0.313). No significant differences were found in the virological failure
rate considering VL> 500 copies/mL (1.4% for MT vs 0% for TT, P = 0.546), VL > 200 cop-
ies/mL (3.4% for MT vs 0% for TT, P = 0.167), or VL > 50 copies/mL (8.2% for MT vs 3.9%
for TT, P = 0.271), nor for the percentage of patients with VL < 200 copies/mL at any time
during the study (91.8% for MT vs 96.2% for TT, P = 0.204). Furthermore, there were no statis-
tical differences in adherence and virological failure between arms (Table 3).
Furthermore, the number of detectable VLs over time did not show significant differences
(for example, 6.6% for MT vs 4.7% for TT, P = 0.253, for VL> 50 copies/mL). The risk of viro-
logical rebound was similar for both arms: the OR of MT versus TT was 1.429 (CI 95% 0.772–
2.646) for VL > 50 copies/mL; and 1.762 (CI 95% 0.584–5.315) for VL> 200 copies/mL.
Genotype testing showed no LPV/r resistance in MT patients with virological failure. All of
them regained virological suppression after restarting prior antiretroviral treatment.
Regarding the development of the immune response, although there was no statistical dif-
ference in total cell counts of CD4 cells/μl, the CD4 percentage of total lymphocytes showed a
significant difference between arms (31.0 ± 8.7% [CI 24.6–37.0] vs 28.7 ± 10.0% [CI 22.0–
35.0], for the MT and the TT arms, respectively; P = 0.039).
Discussion
LPV/r monotherapy is one of the best known options of tailored therapeutic approaches for
patients with persistently suppressed HIV viremia in which fewer than the recommended
Table 2. Patients with adverse events during lopinavir/ritonavir monotherapy compared with triple therapy, and number of adverse events according to grade
severity.
Patients MT
(n = 146)
TT
(n = 76)
N % N % P (Fisher's exact test)
Total of patients with adverse events 26 17.8 11 14.3 0.573
Patients with serious adverse events 6 4.1 1 1.3 0.426
Adverse events MT
(n = 45)
TT
(n = 18)
According to seriousness Serious adverse events (Grade IV) 8 17.8 1 5.6 0.426
Non-serious adverse events (Grade I-III) 37 82.2 17 94.4
Number of non-serious adverse events according to intensity Mild (Grade I) 30 81.1 10 58.8 0.119
Moderate (Grade II) 6 16.2 7 41.2
Severe (Grade III) 1 2.7 0 0
Number of non-serious adverse events according to causality Not related 31 83.8 14 82.4 0.275
Possibly not related 1 2.7 2 11.8
Possibly related 4 10.8 0 0
Probably related 1 2.7 1 5.9
Number of non-serious adverse events according to action taken None 29 78.4 15 88.2 0.457
Dose reduction 0 0 0 0
Temporary treatment interruption 1 2.7 0 0
Permanent treatment discontinuation 4 10.8 0 0
Others 3 8.1 2 11.8
Per-protocol analysis.
MT, monotherapy; TT, triple therapy.
https://doi.org/10.1371/journal.pone.0195068.t002
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standard of three antiretrovirals are used [4]. The primary objective of this study was to mea-
sure the effect on HIV patients’ quality of life of simplifying conventional TT with an MT regi-
men. All patients reported high quality of life scores (over 80), independently of whether self-
administered questionnaires were analysed as a total score or as separate items. After 24 weeks
of follow-up, no statistical differences were observed in most of the quality of life indicators
between patients treated with MT and those in whom TT was continued. Similar results were
reported in the PIVOT trial for the mental and physical health summary scores [35].
It is well known that adherence is a determinant factor of antiretroviral treatment efficacy
and, as such, it is an important variable that must be determined. High rates of adherence were
observed in all patients. The GEEMA and VAS questionnaires did not show any statistical dif-
ference between the two arms.
The degree of patient satisfaction with the monotherapy regimen, measured by the dimen-
sion 1 of the CESTA questionnaire, was significantly greater than in the TT arm. This dimen-
sion registers satisfaction with general health status and treatment, disease control, absence of
side effects, number of pills, dosage schedule, and dietary restrictions. This result could reflect
the advantages of treatment simplification. Particularly, there was greater acceptance of the
number of pills taken by the patients in the experimental arm.
In this study, there were no significant differences in adverse events and viral rebounds
between treatment arms. In contrast with other studies, a low lymphocyte nadir (less than 200
Table 3. Comparison of adherence and virological failure between arms.
Adherent at the end of the follow-up period P
MT TT
N % N %
Last VL undetectable
(<50 copies/mL)
No (> 50) 11 12.5 3 7.0
Yes (< 50) 77 87.5 40 93.0 0.337
Undetectable VL
during the study
Yes 73 83.0 39 90.7
No 15 17.0 4 9.3 0.237
Virological failure
(>500 copies/mL)
Yes 1 1.1 0 0.0
No 88 98.9 43 100.0 1.000
Virological failure
(>200 copies/ml)
Yes 3 3.4 0 0.0
No 86 96.6 43 100.0 0.551
Virological failure
(>50 copies/mL)
Yes 6 6.7 1 2.3
No 83 93.3 42 97.7 0.426
Non-adherent at the end of the follow-up period P
MT TT
N % N %
Last VL undetectable
(<50 copies/mL)
No (> 50) 8 21.1 5 26.3
Yes (< 50) 30 78.9 14 73.7 0.655
Undetectable VL
during the study
Yes 27 71.1 13 68.4
No 11 28.9 6 31.6 0.838
Virological failure
(>500 copies/mL)
Yes 1 2.6 0 0.0
No 37 97.4 19 100.0 1.000
Virological failure
(>200 copies/ml)
Yes 1 2.6 0 0.0
No 37 97.4 19 100.0 1.000
Virological failure
(>50 copies/mL)
Yes 4 10.5 2 10.5
No 34 89.5 17 89.5 1.000
Intent-to-treat analysis.
https://doi.org/10.1371/journal.pone.0195068.t003
Quality of life and efficacy in HIV patients on lopinavir/ritonavir monotherapy
PLOSONE | https://doi.org/10.1371/journal.pone.0195068 April 12, 2018 10 / 15
or less than 100 cells/μl) was not shown to be a risk predictor for VL detection or for virological
failure.
However, although the difference was not significant, TT has been shown to be more effi-
cient than monotherapy in maintaining HIV-1 suppression, with fewer blips and viral
rebounds [22]. As in other studies with PI regimens in monotherapy, detectable VL occurred
in a small group of patients (less than 10%) with no consequences on the appearance of resis-
tance to LPV/r, and in such a way that resuppression of HIV-1 replication is achieved after re-
introduction of the previously withdrawn nucleoside backbone or any other additional antire-
troviral treatment.
With regard to development of the immune response, the fact that the fraction of CD4/total
lymphocytes increased to a greater extent in the TT arm has uncertain significance, and no
conclusions can be drawn. Although an increase in the percentage of CD4 cells may be associ-
ated in some cases with a decrease in the percentage of CD8 cells, and thus with a decrease in
immunological activation, no other activation parameters were measured to further evaluate
this feature.
Almost 85% of ITT population in the MT arm had a VL of < 50 copies/mL at the end of the
study. This outcome could be an indication that the monotherapy simplification strategy with
LPV/r in stable, controlled HIV-1 patients is safe and efficient. While this conclusion is not
novel, it reinforces results from previous studies [36] and supports a simplification strategy
with boosted PI, as already proposed by other groups [37–41].
Previously, the MONARK trial had analysed quality of life as a secondary endpoint in anti-
retroviral-naive patients in MT [42], with the application of 1 questionnaire. The larger sample
size and longer study period of that survey proved useful for evaluating whether MT provides
a better quality of life than the TT regimen, which was shown true in case of the total number
of symptoms, the number of symptoms causing discomfort, and the development in MT
patients of a significant positive perception of their global health status.
The slight differences in patients’ treatment adherence, quality of life, and satisfaction
shown by our study suggest that switching from standard TT to MT may be beneficial. How-
ever, a more obvious gain in quality of life was expected in the monotherapy arm, considering
the simplification of the treatment, despite the twice-a-day administration. These results may
also be due to limitations, such as a reduced statistical power due to sample size, the subjective
nature of the assessment tools, short follow-up and cohort characteristics. Indeed, the study
was carried out on patients who were already tolerating a stable antiretroviral regimen, with a
high quality of life at baseline (VAS score over 80%), so the probability of showing differences
was low a priori. Longer follow-up periods and a greater number of patients may be needed to
demonstrate any change. There has also been a delay in the publication of this article due to
the desire to elaborate on virological data outcomes. This prolonged the data collection period
to perform a post-hoc analysis and rewrite the article for publication. This delay has led to a
loss of interest in the study drug since the study was carried out. However, this study is impor-
tant as it offers new data on the efficacy and safety of MT that could be extrapolated to
darunavir.
In summary, we showed that both regimens exhibited high overall health scores, satisfac-
tion and treatment adherence, and did not lead to significant differences from baseline in VL
or CD4 cell counts. Our results are in general agreement with previous studies and support the
effectiveness of LPV/r as a suitable LDR for some patients, in light of the evidence for main-
tained HIV-1 suppression and potential to avoid the side effects associated with nucleoside
analogue-containing regimens. This strategy also preserves future treatment options in case of
failure, and reduces the economic costs of antiretroviral therapy, while maintaining a very
good quality of life.
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